Subjects: TDS, FVT
OncoSec To Present At The Oppenheimer's 28th Annual Healthcare Conference
SAN DIEGO, March 16, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, Chief Executive Officer of OncoSec, will present at the Oppenheimer 28th Annual Healthcare Conference being held March 20-21, 2018 at the Westin New York Grand Central in New York City.
Mr. O'Connor will present OncoSec's corporate growth strategy and its focus on developing DNA-based intratumoral immunotherapies that utilize the company's proprietary ImmunoPulse® technology, which is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents. In Phase 1 and 2 clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response.
Details of OncoSec's presentation are as follows:
|
Event: |
Oppenheimer & Co. 28th Annual Healthcare Conference | |
|
Date: |
March 20, 2018 | |
|
Time: |
1:20 PM (ET) | |
|
Location: |
The Westin New York Grand Central, New York, NY |
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
To view the live webcast, please access the following link at the time of the presentation: https://www.veracast.com/webcasts/opco/healthcare2018/72115452478.cfm.
An archived version of the webcast will be available for 90 days on OncoSec's website: http://www.oncosec.com.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or "tavo"). In Phase 1 and 2 clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies. In addition to tavo, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform. For more information, please visit www.oncosec.com.
CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
[email protected]
Media Relations:
Janine McCargo / David Schemelia
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
[email protected]
[email protected]
SOURCE OncoSec Medical Incorporated
These press releases may also interest you
|
News published on and distributed by:
